Page 2,414«..1020..2,4132,4142,4152,416..2,4202,430..»

Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphereâ„¢ Cell Therapy

Posted: March 3, 2013 at 4:43 pm

SALT LAKE CITY, Feb. 28, 2013 /PRNewswire/ --Discgenics announces the successful completion of an animal study demonstrating safety and efficacy of its novel therapy for reducing back pain caused by degenerative disc disease. This product, known as Injectable Discosphere Cell Therapy (IDCT), features Discgenics' patented, allogeneic, human disc-derived stem cell technology. The study showed that after one injection of IDCT in degenerated discs there was a restoration of disc height and tissue architecture, while noting no inflammatory response.

Discgenics CEO Flagg Flanagan said, " We are very encouraged by the results of the small animal pilot study as it shows the initial safety and efficacy of IDCT, which is produced from adult human disc-derived stem cells.We are optimistic that these early results will be indicative of our therapy's performance in further animal studies and will accelerate us toward human clinical studies and, ultimately, to an FDA cleared product.We believe this technology will revolutionize the way back pain is treated." Discgenics is currently conducting further studies of safety and efficacy in multiple animal species to support future scientific publications and for use in gaining regulatory clearance.

About Discgenics, Inc.

Discgenics is a privately funded spinal therapeutics company that is utilizing adult human disc stem cells within a tissue engineering approach to treat patients debilitated by degenerative disc disease. News and other information on the company are available at: http://www.discgenics.com.

Read the original here:
Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphereâ„¢ Cell Therapy

Posted in Cell Therapy | Comments Off on Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphereâ„¢ Cell Therapy

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy – Video

Posted: March 3, 2013 at 4:42 pm


Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

See more here:
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy - Video

Posted in Stem Cell Therapy | Comments Off on Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy – Video

Myotonic Muscular Dystrophy Before and After Stem Cell Therapy – Video

Posted: March 3, 2013 at 4:42 pm


Myotonic Muscular Dystrophy Before and After Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

Read more here:
Myotonic Muscular Dystrophy Before and After Stem Cell Therapy - Video

Posted in Stem Cell Therapy | Comments Off on Myotonic Muscular Dystrophy Before and After Stem Cell Therapy – Video

Cerebral Palsy Before and After Stem Cell Therapy Comparison – Video

Posted: March 3, 2013 at 4:42 pm


Cerebral Palsy Before and After Stem Cell Therapy Comparison
Cerebral Palsy Before and After Stem Cell Therapy Comparison video Stem Cell Therapy done at Dr Alok Sharma NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Original post:
Cerebral Palsy Before and After Stem Cell Therapy Comparison - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Cerebral Palsy Before and After Stem Cell Therapy Comparison – Video

Stem Cell Therapy for Autism Part 2 – Video

Posted: March 3, 2013 at 4:42 pm


Stem Cell Therapy for Autism Part 2
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy Psychology assessment: 1) Now his duration of expressing his anger has reduced (ie) previously he would get angry and it would continue for half an hour to 20 minutes. Now it has reduced to 10 minutes. 2) Now his level of understanding and tolerance level has increased (ie) before he would get upset even before his parents spoke whereas now he listens to them and follows commands. 3) Now he has started writing (ie) now he can copy from the book and he can do so for a duration of ½ hour to 1 hour which wasn #39;t possible at all before. 4) Previously he had obsessive features like washing his hands repetitively but now it has reduced. 5) Previously he would disturb others in the classroom by shouting or sitting next to them but now he doesn #39;t disturb others ...

By: neurogenbsi

Originally posted here:
Stem Cell Therapy for Autism Part 2 - Video

Posted in Cell Therapy | Comments Off on Stem Cell Therapy for Autism Part 2 – Video

Stem Cell Therapy for Autism Part 1 – Video

Posted: March 3, 2013 at 4:42 pm


Stem Cell Therapy for Autism Part 1
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy 1. Angry spells are short lasting than before. Earlier, if he used to be upset for half hour at a stretch, now he calms down in 2 minutes. 2. Did not ask for toothpaste for second time which he used to do daily. 3. He does not insist on bathing 2-3 times a day like before. Now, he takes bath once a day. 4. Visits washroom once in 2-3 hours and then washes his hand normally and leaves the washroom. Earlier, he used to go to washroom every hourly and wash his hand, spill water on his clothes and arms. 5. Eye contact attention span improved. 6. Sitting tolerance improved and attends for 30 mins session. 7. Listening skills and observation skills on demand improved. 8. Screaming behavior reduces when given paper tearing activity. 9. His parents feel his ...

By: neurogenbsi

Excerpt from:
Stem Cell Therapy for Autism Part 1 - Video

Posted in Cell Therapy | Comments Off on Stem Cell Therapy for Autism Part 1 – Video

Stem Cell Therapy for Autism Part 1 Tamil – Video

Posted: March 3, 2013 at 4:42 pm


Stem Cell Therapy for Autism Part 1 Tamil
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy 1. Angry spells are short lasting than before. Earlier, if he used to be upset for half hour at a stretch, now he calms down in 2 minutes. 2. Did not ask for toothpaste for second time which he used to do daily. 3. He does not insist on bathing 2-3 times a day like before. Now, he takes bath once a day. 4. Visits washroom once in 2-3 hours and then washes his hand normally and leaves the washroom. Earlier, he used to go to washroom every hourly and wash his hand, spill water on his clothes and arms. 5. Eye contact attention span improved. 6. Sitting tolerance improved and attends for 30 mins session. 7. Listening skills and observation skills on demand improved. 8. Screaming behavior reduces when given paper tearing activity. 9. His parents feel his ...

By: neurogenbsi

Read more:
Stem Cell Therapy for Autism Part 1 Tamil - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stem Cell Therapy for Autism Part 1 Tamil – Video

LA Times: Stem Cell Agency Conflict-of-Interest Response Only a Bandage

Posted: March 3, 2013 at 3:07 am

The Los Angeles Times yesterday modestly praised the $3 billion California stem cell agency for
taking some limited steps to deal with its longstanding conflict of
interest issues.

But the newspaper, which has the largest circulation in the state, said that was more was
needed if the agency plans to have a life after 2017, when funds for
new awards run out.
The Times editorial said,

“After years of resisting all
criticisms of its operations, the California Institute for
Regenerative Medicine
is finally listening — a little.“

The editorial continued,

“Yet the agency isn't exactly
embracing an ethical overhaul. It's doing just enough to address the
criticisms without triggering any oversight from the Legislature. The
modifications are more a bandage than a cure. Like a bandage, they
will probably do, but only for a limited time.”

The board plans to have 13 board
members with ties to recipient institutions voluntarily refrain from
voting on any grants that come before the board, not just the ones to
their institutions.
The Times said December's blue-ribbon
report from the Institute of Medicine identified the make-up of the
board as the “single biggest problem” at the agency. The
editorial cited figures prepared by the California Stem Cell Report
that show that about 90 percent of the $1.8 billion that the board
has awarded has gone to institutions linked to current or past
members of the board. Fifteen out of the 29 current board members
have ties to recipient institutions.
The editorial concluded,

“If the stem cell institute is just a
temporary agency that will last until its public funding runs out —
it plans to give its last grants with existing funds in 2017 — its
planned reforms will probably be enough. But if the institute wants
to be a permanent part of the research landscape — and possibly ask
for more public funding — voluntary recusals are an inadequate
patch. The agency's leaders should admit that the original setup was
flawed and seek a true fix. “

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/4TPMCEI6hDg/la-times-stem-cell-agency-conflict-of.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on LA Times: Stem Cell Agency Conflict-of-Interest Response Only a Bandage

CIRM Director Prieto on Disclosure of Reviewer Financial Interests

Posted: March 3, 2013 at 3:07 am

A member of the governing board of the
$3 billion California stem cell agency is weighing in on an item on
the California Stem Cell Report that called for public disclosure of the financial interests of the scientific reviewers, who make 98
percent of the decisions on awards by the agency.

Francisco Prieto, a Sacramento
physician and a patient advocate member of the board, said in an email:

“ It seems to me there's a bit
of 'damned if we do and damned if we don't' here. If the ICOC (the
agency governing board) decides to listen to some of the members of
the public who come to our meetings and overrule a recommendation of
the Grants Working Group(GWG), we're slammed for letting emotion trump
science, or bowing to special interests. If we just accept the
rankings of the GWG and approve all their recommendations, we're
criticized for not being truly independent.  I think we don't do
it often (for good reason) but should and do retain the right to look
at other factors besides those our scientific reviewers do, and make
our own decisions about funding. We are ultimately responsible, not
the scientific reviewers. 

“As for the issue of their
disclosure of personal conflicts of interest, from what I've read of
the NIH processes, ours are no less strict. The NIH requires that
reviewers disclose any conflicts to their institutions which I
believe must disclose them to the NIH, but I have not seen anything
requiring them to disclose all their personal financial & other
interests publicly, as we (ICOC members) have to.  When we were
assembling our group of reviewers initially, the fear was that many
of the best scientists would turn us down if we required them to make
the kind of personal disclosures we have to. I don't know how many we
might actually lose if that were the case, but as you know we do
require them to disclose to CIRM, and they have to leave the room
when any application for which they have a conflict is discussed.”

Our take: Prieto is right about the
board being perched on the horns of a dilemma, which has a lot to do
with Proposition 71, which created the agency, and American
scientific traditions, which place an extraordinary value on the
“integrity” of the review process. In this case, integrity refers
to adherence to reviewers' scientific judgments.
Proposition 71 placed the legal
authority for grant approvals in the hands of the CIRM board, which
has overridden decisions by reviewers in only 2 percent of the cases
since 2005. However, that was enough, with at least one high profile
case coupled with public appeals, to cause the Institute of Medicine
to raise concerns about the integrity of the CIRM grant review
process. Traditionally, peer reviewers are deemed to be the most
capable of making the scientific decisions about grant applications,
rather than a board appointed by University of California chancellors
and elected state officials.
Yet, if the board concedes the
decisions to the grant reviewers, state law is likely to require
public disclosure of their financial interests, a move that the board
has opposed for years. Former CIRM Chairman Robert Klein repeatedly
advised the board during its public grant approval processes that
reviewers' actions were only ”recommendations” and that the board
was actually making the decisions. However, it has long been apparent
that the reviewers were making the de facto decisions. A CIRM memo in
January confirmed that, producing the 98 percent figure.
The issues involving disclosure by
reviewers, integrity of peer reviews, the language of Proposition 71
and state law are difficult and may, in some cases, be at odds.
However, it makes little difference
what the NIH is doing. It is a much different organization and has
had a history of conflict of interest problems that it has been
trying to work through.
The trend in the academic and
scientific research community has been towards more public disclosure
rather than less because of many well-documented instances of
problems. What is at stake is the public's faith in scientific
research and the integrity of public institutions.
Our thanks to Prieto for his comments
on this important subject.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/OlA8vhJTIsA/cirm-director-prieto-on-disclosure-of.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on CIRM Director Prieto on Disclosure of Reviewer Financial Interests

California Stem Cell Agency: Comparing the Critiques

Posted: March 3, 2013 at 3:07 am

State Controller John Chiang has posted
a useful, side-by-side comparison of critiques of the $3 billion
California stem cell agency, including the Institute of Medicine(IOM)
study, along with the responses from the agency.

Chiang, the state's top fiscal officer,
has additionally posted the initial remarks Jan. 23 by CIRM Chairman
Jonathan Thomas before the stem cell agency governing board on his
plan to deal with the sweeping recommendations of the IOM.
Regardless of one's opinion of the
board's response to the IOM, Thomas adroitly handled the discussion
and vote, not a small accomplishment given the size of the board (29
members) and the legal restrictions involving public meetings. Under
state law, Thomas could not lobby significant numbers of the board in
advance of the meeting. He was restricted to engineering the approval
in a public session, which can easily take on a life of its own given
the unwieldy size of the board and the necessity for public comment.
As for the documents posted by Chiang,
he is chairman of the Citizens Financial Accountability and Oversight
Committee
, the only state body specifically charged with oversight of
the agency and its board. The web site for the committee is the only
location on the Internet where Thomas' prepared remarks and the
comparison can be found.
Chiang's comparison chart includes not
only the IOM study, but last year's performance audit and the Little
Hoover Commission
study in 2009. Missing, however, is the state
auditor's report in 2007 and its recommendation that the agency seek an attorney general's opinion on whether scientific grant reviewers must file a public financial disclosure form.
Here are links to the various
documents: Thomas' prepared comments, Power Point chart used by Thomas,
comparison chart of various studies and the transcript of the Jan. 23 meeting during which the governing board approved its response.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Yb7Eb9xPMvo/california-stem-cell-agency-comparing.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Agency: Comparing the Critiques

Page 2,414«..1020..2,4132,4142,4152,416..2,4202,430..»